OBJECTIVES: To evaluate the impact of long-term outcomes of transarterial embolization (TAE) therapy in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) on the waiting list for liver transplantation (LT). METHODS: We retrospectively evaluated the post-LT patients with HCV-related HCC who received TAE intervention (n=33) and those who had no treatment (n=47) while on the waiting list to determine long-term outcomes. RESULTS: Over a 10-year period, of the 424 patients transplanted with HCV, 80 patients had HCC with a tumor burden within Milan criteria. For the entire study cohort, the mean duration of post-LT follow-up was 3.5 years; mean time of transplant waiting list was 120 days; and median post-LT survival was 8.9 years. The survival rates at 1, 3, 5, and 10 years were 82%, 70%, 55%, and 35%, respectively. From the study cohort, 33 patients received TAE and 47 patients did not while on the waiting list. The 2 groups were well matched, except, that the intervention patients received post-LT interferon more often and had a shorter time on the waiting list (56.2 d) when compared with the no treatment group (164.6 d, P<0.001). Median survival in the TAE group was 4.8 years and 8.9 years in the no treatment group. The recurrence rate was 15.6% in the treatment group and 6.9% in the no therapy group (P=0.275). CONCLUSIONS: Pre-LT transarterial therapy has no benefit on post-LT survival and tumor recurrence in patients with HCV-related HCC who underwent a mean waiting period of <3 months to transplant.
OBJECTIVES: To evaluate the impact of long-term outcomes of transarterial embolization (TAE) therapy in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) on the waiting list for liver transplantation (LT). METHODS: We retrospectively evaluated the post-LT patients with HCV-related HCC who received TAE intervention (n=33) and those who had no treatment (n=47) while on the waiting list to determine long-term outcomes. RESULTS: Over a 10-year period, of the 424 patients transplanted with HCV, 80 patients had HCC with a tumor burden within Milan criteria. For the entire study cohort, the mean duration of post-LT follow-up was 3.5 years; mean time of transplant waiting list was 120 days; and median post-LT survival was 8.9 years. The survival rates at 1, 3, 5, and 10 years were 82%, 70%, 55%, and 35%, respectively. From the study cohort, 33 patients received TAE and 47 patients did not while on the waiting list. The 2 groups were well matched, except, that the intervention patients received post-LT interferon more often and had a shorter time on the waiting list (56.2 d) when compared with the no treatment group (164.6 d, P<0.001). Median survival in the TAE group was 4.8 years and 8.9 years in the no treatment group. The recurrence rate was 15.6% in the treatment group and 6.9% in the no therapy group (P=0.275). CONCLUSIONS: Pre-LT transarterial therapy has no benefit on post-LT survival and tumor recurrence in patients with HCV-related HCC who underwent a mean waiting period of <3 months to transplant.
Authors: S Kubo; S Nishiguchi; K Hirohashi; H Tanaka; T Shuto; O Yamazaki; S Shiomi; A Tamori; H Oka; S Igawa; T Kuroki; H Kinoshita Journal: Ann Intern Med Date: 2001-05-15 Impact factor: 25.391
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Ivo W Graziadei; Heiko Sandmueller; Peter Waldenberger; Alfred Koenigsrainer; Karin Nachbaur; Werner Jaschke; Raimund Margreiter; Wolfgang Vogel Journal: Liver Transpl Date: 2003-06 Impact factor: 5.799
Authors: Einar K Rofstad; Jon-Vidar Gaustad; Tormod A M Egeland; Berit Mathiesen; Kanthi Galappathi Journal: Int J Cancer Date: 2010-10-01 Impact factor: 7.396
Authors: Roberto J Firpi; Manal F Abdelmalek; Consuelo Soldevila-Pico; Roniel Cabrera; Jonathan J Shuster; Douglas Theriaque; Alan I Reed; Alan W Hemming; Chen Liu; James M Crawford; David R Nelson Journal: Liver Transpl Date: 2004-10 Impact factor: 5.799
Authors: J P Bronowicki; D Vetter; F Dumas; K Boudjema; R Bader; A M Weiss; J J Wenger; P Boissel; M A Bigard; M Doffoel Journal: Cancer Date: 1994-07-01 Impact factor: 6.860
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: Nikos Emmanouilidis; Rickmer Peters; Bastian P Ringe; Zeynep Güner; Wolf Ramackers; Hüseyin Bektas; Frank Lehner; Michael Manns; Jürgen Klempnauer; Harald Schrem Journal: J Transplant Date: 2016-01-10